These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 39044275)

  • 1. Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis.
    Shi Y; Zhao L; Wang J; Liu X; Bai Y; Cong H; Li X
    Cardiovasc Diabetol; 2024 Jul; 23(1):269. PubMed ID: 39044275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
    Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N
    Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain.
    Schauer A; Adams V; Kämmerer S; Langner E; Augstein A; Barthel P; Männel A; Fabig G; Alves PKN; Günscht M; El-Armouche A; Müller-Reichert T; Linke A; Winzer EB
    Circ Heart Fail; 2024 Jun; 17(6):e011107. PubMed ID: 38847102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.
    Ni XY; Feng XJ; Wang ZH; Zhang Y; Little PJ; Cao Y; Xu SW; Tang LQ; Weng JP
    Acta Pharmacol Sin; 2024 Aug; 45(8):1604-1617. PubMed ID: 38589689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
    Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
    Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF.
    Trum M; Riechel J; Schollmeier E; Lebek S; Hegner P; Reuthner K; Heers S; Keller K; Wester M; Klatt S; Hamdani N; Provaznik Z; Schmid C; Maier L; Arzt M; Wagner S
    Cardiovasc Res; 2024 Jul; 120(9):999-1010. PubMed ID: 38728438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin directly improves diastolic function in human heart failure.
    Pabel S; Wagner S; Bollenberg H; Bengel P; Kovács Á; Schach C; Tirilomis P; Mustroph J; Renner A; Gummert J; Fischer T; Van Linthout S; Tschöpe C; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Hamdani N; Sossalla S
    Eur J Heart Fail; 2018 Dec; 20(12):1690-1700. PubMed ID: 30328645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
    Chen S; Wang Q; Bakker D; Hu X; Zhang L; van der Made I; Tebbens AM; Kovácsházi C; Giricz Z; Brenner GB; Ferdinandy P; Schaart G; Gemmink A; Hesselink MKC; Rivaud MR; Pieper MP; Hollmann MW; Weber NC; Balligand JL; Creemers EE; Coronel R; Zuurbier CJ
    Basic Res Cardiol; 2024 Oct; 119(5):751-772. PubMed ID: 39046464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
    Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
    Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition.
    Chen S; Overberg K; Ghouse Z; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Biomed Pharmacother; 2024 May; 174():116477. PubMed ID: 38522235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway.
    Mattii L; Moscato S; Ippolito C; Polizzi E; Novo G; Zucchi R; De Caterina R; Ghelardoni S; Madonna R
    Biomed Pharmacother; 2024 Sep; 178():117278. PubMed ID: 39116784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.
    Bayes-Genis A; Iborra-Egea O; Spitaleri G; Domingo M; Revuelta-López E; Codina P; Cediel G; Santiago-Vacas E; Cserkóová A; Pascual-Figal D; Núñez J; Lupón J
    Sci Rep; 2021 Jun; 11(1):12025. PubMed ID: 34103605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
    Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
    Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
    Withaar C; Meems LMG; Markousis-Mavrogenis G; Boogerd CJ; Silljé HHW; Schouten EM; Dokter MM; Voors AA; Westenbrink BD; Lam CSP; de Boer RA
    Cardiovasc Res; 2021 Jul; 117(9):2108-2124. PubMed ID: 32871009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
    Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
    J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
    Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
    Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan Reverses Cardiac Malfunction and Cardiomyocyte Ferroptosis During Heart Failure with Preserved Ejection Fraction via Connexin 43 Signaling Activation.
    Zhang LL; Chen GH; Tang RJ; Xiong YY; Pan Q; Jiang WY; Gong ZT; Chen C; Li XS; Yang YJ
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):705-718. PubMed ID: 36881213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
    Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
    Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
    Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
    Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
    Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
    Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.